Objective To compare the sensitivity of high-risk human papillomavirus (hrHPV) and genotype detection in self-collected urine samples in the morning (U1), and later on (U2), brushbased self-samples (SS), and clinician-taken smears (CTS) for detecting cervical intraepithelial neoplasia grade 2+ (CIN2+) in a colposcopic referral population.
Introduction
Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Its incidence and mortality has decreased in countries with organised cytology screening; 1, 2 however, the sensitivity of a single smear for high-grade cervical intraepithelial neoplasia (CIN2+) varies, and requires a visit to a clinician, leading to frequent repeats of Pap smears over a lifetime. 3 Testing for high-risk human papillomavirus (hrHPV) in clinician-taken smears (CTS) is more sensitive than cytology for CIN2+ and CIN3+, and results from randomised controlled trials have led to the foreseeable implementation of the hrHPV test in several screening programmes. [4] [5] [6] [7] Yet, its requirement for visits to a primary care centre may still be a barrier for participation.
Participation is the main impediment to the effectiveness of a programme, as even in countries with well-organised screening programmes, half of all potentially detectable carcinomas are found in women who have not attended screening programmes. 2 Self-sampling has been proposed to increase participation, as non-responders are more likely to hand in a self-collected sample (SS) of cervicovaginal cells than to respond to a recall for a Pap smear. 8 Testing SS for hrHPV was found to be well accepted among these women, and comparable in performance with a CTS. [9] [10] [11] A novel, alternative method of self-sampling is collecting urine. The main advantage of this method over SS is that the procedure is non-invasive. A recent study showed that first-void urine contained higher concentrations of human and HPV DNA than midstream urine. This fraction contains the most cervicovaginal cells because it is first to pass the external genitalia, taking mucus adherent to the surface with it. 12 Whether the first fraction of urine of the first void of the day (U1), after the mucus has remained unmoved during the night, contains a higher concentration of DNA than fractions taken later during the day (U2) remains to be determined.
The objective of this study was to determine the sensitivity and specificity of hrHPV testing of U1 for the detection of CIN2+ in women with an abnormal Pap smear. In addition, we compared HPV detection results from U1 with urine voided later that day (U2), CTS, or SS. Finally, two different HPV assays were used and compared.
Methods

EVAH study
Women included in the study were part of a prospective cohort of women included in a multicentre study of triage and colposcopic management of women with abnormal smears conducted between August 2010 and September 2015 (EVAH study). 13 The EVAH study aims to evaluate the colposcopic visual appearance of cervical lesions in relation to underlying histology, HPV genotype(s), and molecular parameters, and to study cervical HPV at the tissue level. Women included were aged 18 years or older and had been referred for colposcopy to the Hospital Cl ınic, Barcelona, Spain, because of abnormal cervical cytology.
For the present study, a total of 113 women aged 18-60 years were recruited from the EVAH study. Specimens were collected between September 2014 and March 2015 in Hospital Cl ınic, Barcelona, Spain. The medical ethical board of the Hospital Cl ınic approved this study. All women gave signed informed consent.
Sample collection
For urine sample collection a device that allows the collection of first-void urine (Colli-Pee™, Novosanis, Wijnegem, Belgium) was sent to participating women. This device was delivered to their home, accompanied by an information letter and instructions on use. A picture of the device and the instructions can be found in Figures S1 and S2. Collection tubes contained 4 mL of a buffered lithium dodecyl sulfate solution containing RNA preservative. Women were asked to collect a urine sample of the very first void on the morning of their visit (U1), and to take the sample to the outpatient clinic. The day before their visit women received a telephone call to clarify any ambiguities and to answer questions.
At the outpatient clinic, women were asked to hand in another first-void urine sample (U2) using the same device and a brush-based self-sample of cervicovaginal cells obtained with the Evalyn brush™ (Rovers Medical Devices B.V., Oss, the Netherlands).
Women then underwent a pelvic examination and CTS using a Cervex-Brush (Rovers Medical Devices B.V., Oss, the Netherlands). Women also underwent colposcopydirected biopsy after the application of acetic acid 5% to elicit the acetowhite epithelial response. Colposcopy findings were described following the criteria of the IFCPC. 14 Up to four colposcopy-directed biopsies (CDBs) were collected from different lesions or different regions presenting different colposcopy patterns within one lesion. Distinct areas within a large complex lesion were biopsied separately. When the transformation zone (TZ) was not visible, an endocervical curettage (ECC) was collected. If fewer than four directed biopsies were taken, a biopsy was taken from normal appearing epithelium of the squamocolumnar junction (SCJ; non-directed biopsy).
Questionnaires
To investigate the acceptability of the Colli-Pee and the Evalyn Brush, all women were asked to fill out a short questionnaire (Appendix S1) using a five-point ordinal scale on their general experience, the instructions, and the convenience of both. Participants were also asked for their preferred sampling method.
Urine processing
Samples of urine (16 mL) were stored with 4 mL of an inhouse RNA preserving medium containing a buffered lithium dodecyl sulfate solution at À80°C within 48 hours of collection for up to 3 months before shipping to the Netherlands on dry ice. Molecular testing was performed at DDL Diagnostic Laboratory, Rijswijk, the Netherlands. For DNA isolation from the urine samples, 1000 lL was used to obtain 50 lL of eluate with the MagNa Pure 96 instrument (Roche Diagnostics, Almere, the Netherlands).
SS processing
Brush-based self-samples were stored dry at room temperature for up to 3 months. For shipment to DDL Diagnostic Laboratory, the brushes were placed in a vial containing 1 mL of Thinprep. Vials were vortexed twice for 15 seconds, stored at room temperature (19-22°C) for 30 minutes and then vortexed again, twice, for 15 seconds. Vials were shipped to DDL Diagnostic Laboratory, where 250 lL was used for DNA isolation using NucliSENS easyMAG to obtain 100 lL of DNA.
CTS processing
Cervical samples were transferred to PreservCyt solution (Hologic Corp, Marlborough, MA, USA) for ThinPrep liquid-based cytology and hrHPV testing.
Liquid-based cytology was aliquoted (2 mL) and stored at room temperature until shipment to DDL Diagnostic Laboratory for molecular testing. Thin-layer cytology slides were prepared using the Thinprep T2000 slide processor (Hologic), stained using the Papanicolaou method, evaluated by a cytotechnologist, and confirmed by a pathologist using the revised Bethesda nomenclature. 15 At DDL Diagnostic Laboratory, 250 lL of the aliquot was used for DNA isolation using the NucliSENS easyMAG, obtaining 100 lL of DNA.
Histological processing
All biopsy specimens were collected in separate vials and fixed in 10% formalin before processing and embedding in paraffin wax. Hematoxylin-eosin (H&E) sections were examined by a local pathologist and classified as normal, CIN1, CIN2, CIN3, or invasive carcinoma. In this study, the overall histological diagnosis per case was based on the worst diagnosis found in any specimen from each woman. All biopsies were independently reviewed by a second central gynaecological pathologist. In the case of disagreement between the original and review diagnoses, a third central pathologist reviewed the discordant cases independently. Diagnosis was determined by agreement of two out of three interpretations. In the case of three different diagnoses, the two central pathologists came to a consensus after joint review of the discordant case.
DNA testing
SPF10 PCR-DEIA-LiPA25 version 1 HPV SPF10-LiPA25 version 1 (Labo Bio-medical Products, Rijswijk, the Netherlands, based on licensed Innogenetics technology) uses a short PCR fragment assay to perform broad-spectrum HPV DNA amplification. With this assay a 65-bp fragment of the L1 open reading frame of HPV genotypes is amplified, allowing us to detect at least 69 anogenital HPV genotypes using nine conservative probes in a microtiter hybridization assay (DNAenzyme immunoassay: DEIA) (16) . 16 Line probe assay (LiPA25) was then used to analyse the samples found positive for HPV by DEIA by reverse hybridization with type-specific probes for 25 hrHPV and low-risk types: HPV 18 Genotyping of the amplimers was achieved using the LMNX kit HPV GP HR test using xMAP technology for high-throughput screening (Labo Bio-medical Products, Rijswijk, the Netherlands). 19, 20 RNase P The adequacy of amplifiable human DNA in the urine samples was assessed using a quantitative polymerase chain reaction (qPCR) of the reference human gene RNase P. 21 The PCR mix contained a plasmid spiked at a fixed concentration that functioned as an internal control to detect PCR inhibition. All samples tested positive for RNase P and no PCR inhibition was observed.
Comparison of sampling methods and HPV tests
All samples were tested with the same algorithms. In order to evaluate the concordance of the HPV testing results of all four samples (CTS, SS, U1, U2), positivity for 14 hrHPV genotypes detected with the SPF10 algorithm were compared with the 14 hrHPV types (16, 18, 31, 33, 35 , 39, 45, 51, 52, 56, 58, 59, 66, and 68) detected with the GP5+/ 6+ algorithm and considered important for the detection of CIN2+ lesions. For comparison of hrHPV positivity, results were concordant when both samples were either hrHPV positive or hrHPV negative, or were discordant when one of the sample types was hrHPV positive and the other was not. For comparison of detected genotypes, results were then classified as identical, compatible (at least one type found in both samples), or discordant.
Statistical analysis
Results were analysed using IBM SPSS 22.0 for Windows (Chicago, IL, USA). The level of statistical significance was set at P ≤ 0.05 for all tests. The level of agreement was determined using Cohen's kappa statistics. For a comparison of positivity rates the two-tailed McNemar's test was used.
The j value with a 95% confidence interval (95% CI) was calculated as a measure of agreement between the HPV genotypes observed in the different sampling methods. HPV agreement was defined as slight (j ≤ 0.20), weak (j = 0.21-0.40), moderate (j = 0.41-0.60), strong (j = 0.61-0.80), near perfect (j = 0.81-0.99), and perfect (j = 1.000). 22 The efficacy of hrHPV testing for CIN2+ detection of CTS, SS, U1, and U2 was evaluated as sensitivity, specificity, and positive (PPV) and negative predictive value (NPV).
Results
Study cohort
From 91 out of 113 women, a complete set of CTS, SS, U1, and U2 samples were available for analysis. Twelve women were excluded because at least one of the samples had not been collected. All samples were positive for RNase P and suitable for analysis. The human DNA concentrations of the morning first-void urine sample and the first-void urine sample from later during the day were compared. The average human DNA concentration was 15 ng/lL in U1 and 21 ng/lL in U2 (P = 0.225; 95% CI -16.61, 3.93).
All patients completed the questionnaire and had a cytological diagnosis: 28 (30.8%) were classified as negative, 11 (12.1%) as atypical squamous cells of undetermined significance (ASC-US), nine (9.9%) as atypical squamous cells, cannot exclude high-grade lesion (ASC-H), 28 (30.8%) as low-grade squamous intraepithelial lesion (LSIL), and 15 (16.5%) as high-grade squamous intraepithelial lesion (HSIL). The worst histological diagnosis was negative in 50 women (54.9%), CIN1 in 22 women (24.2%), CIN2 in 13 women (14.3%), and CIN3 in six women (6.6%).
Detection of hrHPV
Comparison of hrHPV tests Without consideration of genotype, 68 women tested hrHPV positive on the CTS, 66 women tested positive on the SS, 67 tested positive on U1, and 70 tested positive on U2 with the SPF10 assay. With the GP5+/6+ assay, 62 women tested positive on the CTS, 59 tested positive on the SS, 60 tested positive on U1, and 60 tested positive on U2. The comparison of hrHPV detection between SPF10 and GP5+/6+ for CTS, SS, U1, and U2 is shown in Table 1 . Good agreement for all sample types was found, with kappa values of 0.74-0.82. The SPF10 test showed more HPV positivity than the GP5+/6+ test, which was expected given the difference in sensitivity. Nonetheless, the agreement between both hrHPV assays was strong to near perfect for all sample types.
Furthermore, all samples were compared for concordance of positivity for the 14 hrHPV genotypes detected by the SPF10 and GP5+/6+ test (Table 2 ) between sample types (CTS versus U1, U2, or SS; SS versus U1 or U2; U2 versus U1). With the SPF10 system the agreement between all sample types was near perfect, with kappa values of 0.81-0.92. With the GP5+/6+ system, strong to near-perfect agreement was found, with kappa values of 0.73-0.85.
hrHPV genotype concordance between specimen types
Comparisons between different sample types for the detection of 14 individual hrHPV genotypes by SPF10 (Table S1 ) and GP5+/6+ (Table S2) were made. There was near-perfect agreement on genotype between U1 and U2 with both the SPF10 system (j = 0.90) and the GP5+/6+ system (j = 0.85). The comparison of the GP5+/6+ results of SS and CTS for any genotype shows near-perfect agreement (j = 0.81). All other comparisons for genotype between sample types result in strong agreements (j = 0.74-0.77).
The results that emerged from the comparison of sample types at genotype level with the SPF10 assay can be found in Table S3 , and the comparison of genotypes found with the GP5+/6+ assay can be found in Table S4 . With both tests, most samples show identical genotyping results. Most discordant results rely on one of the two samples being hrHPV negative, with the other sample being hrHPV positive, rather than both samples showing different hrHPV genotypes. Table 1 . Agreement between the analytically sensitive SPF10 test and the clinically validated GP5+/6+ test on the detection of 14 hrHPV genotypes, for clinician-taken smear (CTS), self-sample (SS), morning first-void urine (U1), and first void-urine from later during the day (U2) Results from individual genotype comparisons using SPF10 and GP5+/6+ are shown in Tables S5 and S6 .
Detection of CIN lesions
All women have been biopsied. In this group of 91 women, CIN3 was detected in six women (6.6%) and CIN2 was detected in 13 women (14.2%). All CIN3 lesions were found to be hrHPV positive by SPF10 and GP5+/6+ in CTS, SS, U1, and U2 (Table 3 ). All four types of sample show a high sensitivity for the detection of CIN2+ lesions with both SPF10 and GP5+/6+ (Table 4) , without any significant differences. The specificities for CIN2+ detection in CTS, SS, U1, and U2 when using SPF10 or GP5+/6+ did not significantly differ.
Questionnaire
The overall rating of the CTS, SS, and urine sampling by all 91 women resulted in an average score of 7.6 out of 10 for CTS, 8.1 for SS, and 8.6 for the urine sampling (P < 0.005). Table S7 shows the results of the questions on the topics of comfort, instructions, convenience, and convenience compared with CTS for the SS using the Evalyn brush and urine sampling using the Colli-Pee. A total of 82 women (90.1%) rated the convenience of the SS compared with CTS as good to excellent, and 81 women (89.0%) rated the urine sampling as good to excellent compared with CTS. Two women rated the convenience of SS compared with CTS as poor. No other sampling issues were scored as poor.
Discussion
Main findings
Clinician-taken smears, brush-based self-sampling, morning first-void urine and first-void urine from later during the day all showed similar high sensitivity for the detection of CIN2+ in this referral population, measured with two different hrHPV tests (the highly sensitive SPF10 LiPA 25, version 1 assay or the clinically validated GP5+/6+ assay). None of the samples or assays missed CIN3.
For SPF10 the sensitivity for CIN2+ detection in CTS, SS, and U2 was all 100%, with a near-perfect agreement between the four different types of samples (j = non-calculable [NC]-1.00). With the GP5+/6+ assay, the sensitivity was 95% for all sample types, with strong agreement between all samples (j = NC-1.00).
Strengths and limitations
The main strength of this study is that we used paired urine samples, vaginal samples, and cervical samples that Table 2 . Agreement on hrHPV positivity, not considering genotyping, in clinician-taken smear (CTS), self-sample (SS), morning first-void urine (U1), and first-void urine from later during the day (U2), tested by SPF10 and GP5+/6+ Table 3 . Overall positivity for 14 hrHPV genotypes by SPF10 and GP5+/6+ assay in clinician-taken smear (CTS), self-sample (SS), morning first-void urine (U1), and first-void urine from later during the day (U2) 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% Total (n = 91) n = 67 n = 62 n = 66 n = 59 n = 67 n = 60 n = 70 n = 60
were all collected and stored at the same time and under the same circumstances. The collection of first-void urine was standardised using a device that was developed to collect only the first fraction of urine. Samples were all stored in preservative and at -80°C shortly after collection, thereby optimising the storage conditions. Additionally, both a cytological and histological sample were taken, thereby providing a histological end point for all women. A limitation of our study is that it was conducted in a small population of women referred to one colposcopy clinic after an abnormal Pap smear. In this selected population, the hrHPV positivity rate and CIN2+ rate are high (73.6% and 20.8%, respectively), and these results cannot be directly extrapolated to a screening population. The confidence intervals around both sensitivity and specificity are quite wide, and a larger study of a screening population is needed.
Interpretation
Several studies that focused on the role of self-sampling in screening have been published. Bosgraaf et al. 23 showed that the Evalyn brush is also suitable for screening purposes, and Burroni et al. 24 found that urine is suitable for HPV detection and has high concordance with HPV detected in clinician-taken smears. No histological diagnoses were available for that study. A study by Stanczuk et al. found the detection of CIN3+ was >90% when testing urine samples with the for cervical smears clinically validated Cobas 4800 assay. 25 There is need for a study focusing on the detection of CIN2+ and CIN3+ lesions in a screening population, including those who do not attend for a CTS, that should include validated clinical hrHPV testing and sensitive HPV detection systems such as SPF10 to assess the utility of urine sampling for cervical cancer prevention through screening.
Our results match with results previously found by Stanczuk et al., 25 and are higher than sensitivities previously found in other studies comparing HPV detection by SS and CTS. 26, 27 The specificity with the GP5+/6+ was higher than with the SPF10 assay (42 and 32% in U1, and 42 and 29% in U2, respectively), but no significant differences were found between the different types of samples. On the genotype level a strong to near-perfect agreement was found between all samples for both SPF10 and GP5+6+, with discordant results not showing any particular pattern with regards to the type of sample.
Conclusion
In this study, first-void urine samples appeared to be suitable for CIN2+ detection, through HPV testing with high analytical and clinical sensitivity, as validated by cliniciantaken samples. Analyses performed on genotype concordance imply that the HPV found in urine is representative of the HPV found in the cervix, with the high concordance between the two urine samples demonstrating the reproducibility of results. When comparing morning first-void urine with first-void urine from later in the day, 5.5% of the patients showed discordant results with SPF10. All five patients had an HPV negative U1 and HPV positive U2, with histological diagnoses being negative for four patients and CIN2 found in one patient. With the GP5+/6+, 8.8% of the patients had discordant HPV results in U1 and U2, with U2 being the only sample testing positive in half of the cases. Our results suggest that there is no advantage in testing morning first-void urine over a portion of first-void urine that was collected at a later time during the day. The fraction of the urine appears to be more important than the timing, which is in line with results from a recent study by Senkomago et al. comparing different fractions and collecting times. 28 A similar quantity of human DNA was collected in both samples but the proportion of cells originating from the urinary tract or from the genital tract and cervix remains to be determined.
Both the SS and the urine sampling were rated as excellent overall by most of the women. Instructions were clear Table 4 . Sensitivity and specificity of hrHPV testing for CIN2+ detection in clinician-taken smear (CTS), self-sample (SS), morning first-void urine (U1), and first-void urine from later during the day (U2), tested with SPF10 and GP5+/6+ and the devices were easy to use. A great advantage of both samples is that they can be sent by mail for collecting samples at home.
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